Search - tctmd.com

Displaying 1 - 20 of 29

Sort: Relevancy | Date

Presentation TCT 2021

Equipoise Is a Myth: NOACs Will Be Superior to LAAO

Presenter: Renato D. Lopes

November 06, 2021

Presentation TCT 2021

Featured Lecture: Clinical Outcomes of LAAO versus NOACS in Atrial Fibrillation in Patients with Prior Ischemic Stroke: Is There Room for Improvement in Clinical Outcomes?

Presenter: Jens Erik Nielsen-Kudsk

November 04, 2021

Presentation TCT 2019

Reversal Strategies for Warfarin and NOACs: The Essentials

Presenter: Teresa Carman

September 27, 2019

Presentation TCT 2019

Switch Therapies/ USE NOACs Instead of Coumadin

Presenter: Dominick Angiolillo

September 27, 2019

Presentation TCT 2019

LAA Closure vs. NOACs: Pros and Cons, PRAGUE 17, and Additional Trials

Presenter: Vivek Reddy

September 26, 2019

Presentation TVT 2019

Critical Appraisal of the Advantages and Limitations of Warfarin, NOACs, and Ablation in Patients With Non-Valvular Atrial Fibrillation

Presenter: DJ Lakkireddy

June 13, 2019

Presentation TCT 2018

Debate: Is LAA Closure a Valid Alternative for Patients With No or Mild Contraindications to Anticoagulants? No NOACs Are Strongly Preferred to LAA Closure!

Presenter: James B. Hermiller Jr, David Hildick-Smith, Freek W.A. Verheugt

September 24, 2018

Presentation JIM 2018

Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing PCI: "Dual Therapy is the right choice”

Presenter: Roxana Mehran

February 23, 2018

Presentation TCT 2017

Amulet: Data Synthesis and Ongoing Trials

Presenter: William A. Gray, Vivek Y. Reddy, Fabian Nietlispach

October 30, 2017

Presentation TCT 2017

WATCHMAN: Data Synthesis and Ongoing Trials

Presenter: William A. Gray, Vivek Y. Reddy

October 30, 2017

Presentation TCT 2017

Do the PIONEER and RE-DUAL Results Alter LAA Closure Decisions?

Presenter: William A. Gray, Vivek Y. Reddy, C. Michael Gibson

October 30, 2017

Presentation TCT 2017

Should the Improved Results With NOACs Compared to Warfarin Change LAA Closure Decisions?

Presenter: William A. Gray, Vivek Y. Reddy, Kurt Huber

October 30, 2017

Presentation TCT 2017

Atrial Fibrillation and PCI/ACS: NOACs, Dual Therapy, and Triple Therapy

Presenter: Thomas H. Maloney, C. Michael Gibson

October 30, 2017

Presentation TCT 2017

Strengths and Limitations of VKA and NOACs in Clinical Practice

Presenter: Christopher B. Granger, Horst Sievert

October 30, 2017

Presentation LAA 2017

Warfarin and NOACs in Non-Valvular Atrial Fibrillation

Presenter: Gregg W. Stone

July 21, 2017

Presentation

New Oral Anticoagulants: Are the Best Options

Presenter: Roberta Rossini

February 10, 2017

Presentation TCT 2016

Debate: Is Left Atrial Appendage Closure Underutilized? No, NOACs Have the Best Efficacy and Safety Profile for Most Patients!

Presenter: Andreas Baumbach, David Hildick-Smith, Jai-Wun Park

November 01, 2016

Presentation TCT 2016

TCT 53: Thromboembolic Event Rate Is Elevated With Lower Adherence to Warfarin and NOACs

Presenter: Neal S. Kleiman, David F. Kong, Jeffrey R Winterfield

October 31, 2016

Presentation TCT 2016

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? No A Combination of Antiplatelet Agents and Warfarin/NOACs Shoud Be Tried First!

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Presenter: Vivek Y. Reddy, Steven J. Yakubov

October 30, 2016

Advertisement

Equipoise Is a Myth: NOACs Will Be Superior to LAAO

Featured Lecture: Clinical Outcomes of LAAO versus NOACS in Atrial Fibrillation in Patients with Prior Ischemic Stroke: Is There Room for Improvement in Clinical Outcomes?

Reversal Strategies for Warfarin and NOACs: The Essentials

Switch Therapies/ USE NOACs Instead of Coumadin

LAA Closure vs. NOACs: Pros and Cons, PRAGUE 17, and Additional Trials

Critical Appraisal of the Advantages and Limitations of Warfarin, NOACs, and Ablation in Patients With Non-Valvular Atrial Fibrillation

Debate: Is LAA Closure a Valid Alternative for Patients With No or Mild Contraindications to Anticoagulants? No NOACs Are Strongly Preferred to LAA Closure!

Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing PCI: "Dual Therapy is the right choice”

Amulet: Data Synthesis and Ongoing Trials

WATCHMAN: Data Synthesis and Ongoing Trials

Do the PIONEER and RE-DUAL Results Alter LAA Closure Decisions?

Should the Improved Results With NOACs Compared to Warfarin Change LAA Closure Decisions?

Atrial Fibrillation and PCI/ACS: NOACs, Dual Therapy, and Triple Therapy

Strengths and Limitations of VKA and NOACs in Clinical Practice

Warfarin and NOACs in Non-Valvular Atrial Fibrillation

New Oral Anticoagulants: Are the Best Options

Debate: Is Left Atrial Appendage Closure Underutilized? No, NOACs Have the Best Efficacy and Safety Profile for Most Patients!

TCT 53: Thromboembolic Event Rate Is Elevated With Lower Adherence to Warfarin and NOACs

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? No A Combination of Antiplatelet Agents and Warfarin/NOACs Shoud Be Tried First!

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content